Imagion Biosystems Limited has announced a supplementary prospectus (Supplementary Prospectus) which shall be read with the prospectus dated 28 October 2019 (Prospectus) and issued by Imagion Biosystems Limited (Company or IBX).
Read the supplementary prospectus.
Imagion Initiates Manufacturing of MagSense® Drug for Phase 2 Clinical Study on HER2+ Breast Cancer
February 19, 2025
MELBOURNE – Imagion Biosystems (Company) (ASX : IBX), a company dedicated to improving healthcare outcomes through the early detection of cancer, is pleased to announce